Misplaced Pages

Temoporfin: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively
Page 1
Page 2
← Previous editContent deleted Content addedVisualWikitext
Revision as of 00:58, 3 September 2011 editBogBot (talk | contribs)Bots53,132 edits populated new fields in {{drugbox}} and reordered per bot approval. Report errors and suggestions to User_talk:BogBot← Previous edit Latest revision as of 10:42, 8 November 2023 edit undoOAbot (talk | contribs)Bots440,440 editsm Open access bot: doi updated in citation with #oabot. 
(20 intermediate revisions by 17 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}
{{Drugbox {{Drugbox
| verifiedrevid = 442310797 | verifiedrevid = 448134770
| IUPAC_name = 3,3',3<nowiki>''</nowiki>,3<nowiki>'''</nowiki>-(2,3-dihydroporphyrin-5,10,15,20-tetrayl)tetraphenol | IUPAC_name = 3,3',3<nowiki>''</nowiki>,3<nowiki>'''</nowiki>-(2,3-dihydroporphyrin-5,10,15,20-tetrayl)tetraphenol
| image = Temoporfin.png | image = Temoporfin.png
Line 7: Line 8:
| tradename = | tradename =
| Drugs.com = {{drugs.com|international|temoporfin}} | Drugs.com = {{drugs.com|international|temoporfin}}
| licence_EU = Foscan | licence_EU = yes
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X --> | pregnancy_US = <!-- A / B / C / D / X -->
Line 16: Line 17:
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> | legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = Rx-only | legal_status = Rx-only
| routes_of_administration = | routes_of_administration =


<!--Pharmacokinetic data--> <!--Pharmacokinetic data-->
Line 23: Line 24:
| metabolism = | metabolism =
| elimination_half-life = | elimination_half-life =
| excretion = | excretion =


<!--Identifiers--> <!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 122341-38-2 | CAS_number = 122341-38-2
| ATC_prefix = L01 | ATC_prefix = L01
Line 33: Line 35:
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = | DrugBank =
| ChEMBL = 383675
| UNII_Ref = {{fdacite|correct|FDA}} | UNII_Ref = {{fdacite|correct|FDA}}
| UNII = FU21S769PF | UNII = FU21S769PF
| KEGG_Ref = {{keggcite|correct|kegg}} | KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D06066 | KEGG = D06066
| ChemSpiderID = 54754


<!--Chemical data--> <!--Chemical data-->
| chemical_formula = | chemical_formula =
| C=44 | H=32 | N=4 | O=4 | C=44 | H=32 | N=4 | O=4
⚫ | smiles = C1CC2=NC1=C(C3=CC=C(N3)C(=C4C=CC(=N4)C(=C5C=CC(=C2C6=CC(=CC=C6)O)N5)C7=CC(=CC=C7)O)C8=CC(=CC=C8)O)C9=CC(=CC=C9)O
| molecular_weight = 680.74 g/mol
| StdInChI = 1S/C44H32N4O4/c49-29-9-1-5-25(21-29)41-33-13-15-35(45-33)42(26-6-2-10-30(50)22-26)37-17-19-39(47-37)44(28-8-4-12-32(52)24-28)40-20-18-38(48-40)43(36-16-14-34(41)46-36)27-7-3-11-31(51)23-27/h1-17,19,21-24,46-47,49-52H,18,20H2/b41-33-,41-34-,42-35-,42-37-,43-36-,43-38-,44-39-,44-40-
⚫ | smiles = C1CC2=NC1=C(C3=CC=C(N3)C(=C4C=CC(=N4)C(=C5C=CC(=C2C6=CC(=CC=C6)O)N5)C7=
| StdInChIKey = LYPFDBRUNKHDGX-LWQDQPMZSA-N
}} }}


'''Temoporfin''' (]) is a ] (based on ]) used in ] for the treatment of ] of the ]<ref name="pmid17516041">{{cite journal |author=Lorenz KJ, Maier H |title= |language=German |journal=HNO |volume=56 |issue=4 |pages=402–9 |year=2008 |month=April |pmid=17516041 |doi=10.1007/s00106-007-1573-1 |url=}}</ref> '''Temoporfin''' (]) is a ] (based on ]) used in ] for the treatment of ] of the ]<ref name="pmid17516041">{{cite journal | vauthors = Lorenz KJ, Maier H | title = | language = de | journal = Hno | volume = 56 | issue = 4 | pages = 402–409 | date = April 2008 | pmid = 17516041 | doi = 10.1007/s00106-007-1573-1 }}</ref>
.<ref name=OGB2009>{{cite news |url=http://findarticles.com/p/articles/mi_qa3931/is_200909/ai_n42040200/pg_7/ |title=Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy. Photochemistry and Photobiology, Sep/Oct 2009 |author=O'Connor, Aisling E, Gallagher, William M, Byrne, Annette T | work=Photochemistry and Photobiology |year=2009}}</ref> .<ref name="O'Connor_2009">{{cite journal | vauthors = O'Connor AE, Gallagher WM, Byrne AT | title = Porphyrin and nonporphyrin photosensitizers in oncology: preclinical and clinical advances in photodynamic therapy | journal = Photochemistry and Photobiology | volume = 85 | issue = 5 | pages = 1053–1074 | year = 2009 | doi = 10.1111/j.1751-1097.2009.00585.x | pmid = 19682322 | s2cid = 205950773 | doi-access = free }}</ref>
It is marketed in the ] under the brand name '''Foscan'''. The ] deemed Foscan non-approvable in 2000. The EU approved its use in June 2001.<ref>http://www.highbeam.com/doc/1P2-18794532.html Foscan approval saves Scotia's skin.</ref> It is marketed in the ] under the brand name '''Foscan'''. The U.S. ] (FDA) declined to approve Foscan in 2000. The EU approved its use in June 2001.<ref>{{cite web | url = http://www.highbeam.com/doc/1P2-18794532.html | work = HighBeam | title = Foscan approval saves Scotia's skin. | archive-url = https://web.archive.org/web/20121104175701/http://www.highbeam.com/doc/1P2-18794532.html | archive-date = 2012-11-04 }}</ref>


Good results were obtained in 21 of 35 patients treated in Germany.<ref>{{cite journal | vauthors = Lorenz KJ, Maier H | title = Photodynamic therapy with meta-tetrahydroxyphenylchlorin (Foscan) in the management of squamous cell carcinoma of the head and neck: experience with 35 patients | journal = European Archives of Oto-Rhino-Laryngology | volume = 266 | issue = 12 | pages = 1937–1944 | date = December 2009 | pmid = 19290535 | doi = 10.1007/s00405-009-0947-2 | s2cid = 5892034 }}</ref>
Good results were obtained in 21 of 35 patients treated in Germany.<ref>http://www.springerlink.com/content/g74w224824v8l013/</ref>


It is photoactivated at 652&nbsp;nm<ref name="O'Connor_2009"/> i.e. by red light.
It is photoactivated at 652&nbsp;nm<ref>{{cite news| url=http://findarticles.com/p/articles/mi_qa3931/is_200909/ai_n42040200/pg_7/ | work=Photochemistry and Photobiology | title=Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy | year=2009}}</ref> i.e. by red light.


Patients can remain photosensitive for several weeks after treatment.<ref name=OGB2009/> Patients can remain photosensitive for several weeks after treatment.<ref name="O'Connor_2009"/>


==Further reading== == References ==
{{reflist|30em}}
*


== Further reading ==
==References==
{{Reflist}} {{refbegin}}
* {{cite journal | vauthors = Marchal S, François A, Dumas D, Guillemin F, Bezdetnaya L | title = Relationship between subcellular localisation of Foscan and caspase activation in photosensitised MCF-7 cells | journal = British Journal of Cancer | volume = 96 | issue = 6 | pages = 944–51 | date = March 2007 | pmid = 17325708 | pmc = 2360096 | doi = 10.1038/sj.bjc.6603631 }}
{{refend}}


{{Chemotherapeutic agents}} {{Chemotherapeutic agents}}
Line 65: Line 72:
] ]
] ]



{{antineoplastic-drug-stub}} {{antineoplastic-drug-stub}}

]